

Please type a plus sign (+) inside this box →

PTO/SB/21 (08-00)

Approval for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
P#8  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.




## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

TRANSMITTAL FORM  (to be used for all correspondence after initial filing)	Application Number	10/054,579	
	Filing Date	Jan 22, 2002	
	First Named Inventor	Turner, Jr., C. Alexander	
	Group Art Unit	1643	
	Examiner Name	Not Yet Assigned	
Total Number of Pages in This Submission	6 pgs + 8 references	Attorney Docket Number	LEX-0300-USA


ENCLOSURES (check all that apply)			
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group	
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences	
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)	
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information	
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter	
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): - Return Postcard - Supplemental Form PTO1449 and copies of 8 References - Copy of International Search Reports as Reference # CW	
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer		
<input checked="" type="checkbox"/> Supplemental Information Disclosure Statement	<input type="checkbox"/> Request for Refund		
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____		
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	<input type="checkbox"/> Remarks		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53			

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Lexicon Genetics Incorporated Lance K. Ishimoto Reg. No. 41,866	
Signature	 DAVID W. HESLER Reg. No. 41,071	24231 PATENT TRADEMARK OFFICE
Date	February 18, 2003	

### CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Arlington, VA 22202 on this date:

Typed or printed name	Michelle.Klein
Signature	
	Date
	February 18, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicant(s):	Turner and Mathur	
Application No.:	10/054,579	
Filed:	January 22, 2002	Group Art Unit: 1643
Title:	Novel Human Kinases and Polynucleotides Encoding the Same	Examiner: To Be Assigned
Attorney Docket No.: LEX-0300-USA		

Assistant Commissioner for Patents  
Box AF  
Arlington, VA 22202

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

This Supplemental Information Disclosure Statement is submitted:

- under 37 CFR 1.97(b), or  
(Within three months of filing national application; or date of entry of international application; or before mailing date of first office action on the merits; whichever occurs last)
- under 37 CFR 1.97(c) together with either a:  
 Certification under 37 CFR 1.97(e), or  
 a \$240.00 fee under 37 CFR 1.17(p), or  
(After the CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
- under 37 CFR 1.97(d) together with a:  
 Certification under 37 CFR 1.97(e), and  
 a petition under 37 CFR 1.97(d)(2)(ii), and  
 a \$130.00 petition fee set forth in 37 CFR 1.17(i)(1).  
(Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)

Applicant(s) submit herewith Form PTO 1449-Information Disclosure Citation together with copies, of patents, publications or other information of which applicant(s) are aware, which applicant(s) believe(s) may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56.



The relevance of the attached references is that under 37 CFR § 1.97 (e)(1) each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application corresponding to the above-identified application not more than three (3) months prior to the filing of this Information Disclosure Statement.

Applicant submits that the above references taken alone or in combination neither anticipate nor render obvious the present invention. Consideration of the foregoing in relation to this application is respectfully requested.

The Commissioner is hereby authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement to Lexicon Genetics Deposit Account No. 50-0892. A copy of this sheet is enclosed.

It is requested that the information disclosed herein be made of record in this application.

Respectfully submitted,

February 18, 2003  
Date

*Lance K. Ishimoto by David W. Hester* DAVID W. HESTER  
Reg. No. 41,866

LEXICON GENETICS INCORPORATED  
8800 Technology Forest Place  
The Woodlands, TX 77381  
(281) 863-3333



24231

PATENT TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicant(s):	Turner and Mathur	
Application No.:	10/054,579	
Filed:	January 22, 2002	Group Art Unit: 1643
Title: Novel Human Kinases and Polynucleotides Encoding the Same		Examiner: To Be Assigned
Attorney Docket No.: LEX-0300-USA		

FEB 26 2003  
TECH CENTER 1600/2900  
RECEIVED

Assistant Commissioner for Patents  
Box AF  
Arlington, VA 22202

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

This Supplemental Information Disclosure Statement is submitted:

under 37 CFR 1.97(b), or

(Within three months of filing national application; or date of entry of international application; or before mailing date of first office action on the merits; whichever occurs last)

under 37 CFR 1.97(c) together with either a:

Certification under 37 CFR 1.97(e), or  
 a \$240.00 fee under 37 CFR 1.17(p), or

(After the CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

under 37 CFR 1.97(d) together with a:

Certification under 37 CFR 1.97(e), and  
 a petition under 37 CFR 1.97(d)(2)(ii), and  
 a \$130.00 petition fee set forth in 37 CFR 1.17(i)(1).

(Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)

Applicant(s) submit herewith Form PTO 1449-Information Disclosure Citation together with copies, of patents, publications or other information of which applicant(s) are aware, which applicant(s) believe(s) may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56.



24231

PATENT TRADEMARK OFFICE

The relevance of the attached references is that under 37 CFR § 1.97 (e)(1) each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application corresponding to the above-identified application not more than three (3) months prior to the filing of this Information Disclosure Statement.

Applicant submits that the above references taken alone or in combination neither anticipate nor render obvious the present invention. Consideration of the foregoing in relation to this application is respectfully requested.

The Commissioner is hereby authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement to Lexicon Genetics Deposit Account No. 50-0892. A copy of this sheet is enclosed.

It is requested that the information disclosed herein be made of record in this application.

Respectfully submitted,

February 18, 2003

Date

*Lance K. Ishimoto by David W. Deller* DAVID W. DELLER  
Reg. No. 41,071

Lance K. Ishimoto

Reg. No. 41,866

LEXICON GENETICS INCORPORATED  
8800 Technology Forest Place  
The Woodlands, TX 77381  
(281) 863-3333



24231

PATENT TRADEMARK OFFICE

Please type a plus sign (+) inside this box → □

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

**SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Sheet

1 of

1

Application Number	10/054,579
Filing Date	January 22, 2002
First Named Inventor	Turner
Group Art Unit	1643
Examiner Name	Not Yet Assigned

Attorney Docket Number LEX-0300-USA

TECH CENTER 1600-2900  
FEB 26 2003  
RECEIVED

Sheet

1 of

1

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office	Number <sup>4</sup>	Kind Code <sup>5</sup>				
	CP		WO 01/81588 A2		Millennium Pharmaceuticals	11-01-2001		

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CQ	DATABASE EMBL 'Online! EBI, Hinxton, Cambridgeshire, U.K.; 8 June 1998, STANCHI ET AL: "Homo sapiens mRNA for putative serine/threonine protein kinase, partial" Database accession no. AJ06701, XP002227865.	
	CR	DATABASE SWISSPROT 'Online! EBI, Hinxton, Cambridgeshire, U.K.; 1 July 1998, STANCHI ET AL: "Putative serine/threonine protein kinase (Fragment)." Database accession no. 060843, XP002227866.	
	CS	HANKS S K ET AL: "PROTEIN KINASE CATALYTIC DOMAIN SEQUENCE DATABASE: IDENTIFICATION OF CONSERVED FEATURES OF PRIMARY STRUCTURE AND CLASSIFICATION OF FAMILY MEMBERS: MELK-SYSTEME BOU-MATIC, OLDENBURG, DE, vol. 200, 1991, pages 38-62, XP000563379, page 38-page 62.	VED
	CT	HANKS S K ET AL: "THE PROTEIN KINASE FAMILY: CONSERVED FEATURES AND DEDUCED PHYLOGENY OF THE CATALYTIC DOMAINS" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 241, no. 4861, 1 July 1988, pages 42-52, XP000613735, ISSN: 0036-8075, page 42 - page 52.	
	CU	HANKS S K ET AL: "THE EUKARYOTIC PROTEIN KINASE SUPERFAMILY: KINASE (CATALYTIC) DOMAIN STRUCTURE AND CLASSIFICATION" FASEB JOURNAL, FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD, US, vol. 9, May 1995, pages 576-596-, XP001078836, issn: 0892-6638, page 576-page 596.	
	CV	HANKS S K ET AL: "USE OF DEGENERATE OLIGONUCLEOTIDE PROBES TO IDENTIFY CLONES THAT ENCODE PROTEIN KINASES" METHODS IN ENZYMOLOGY, ACADEMIC PRESS INC, SAN DIEGO, CA, US, vol. 200, 1991, pages 525-532- XP001096015, ISSN: 0076-6879, page 525 - page 532.	
	CW	International Search Report	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next co to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent document indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard 1 possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to compl should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissio Patents, Washington, DC 20231.